What do you make of the fact that the FDA argument here rests solely on the lack of a good and stable raw material supplier - not one word in there about lack of "sameness" or failure to meet their 5 criteria?
How can they comment on Amphastar meeting the sameness criterion when they have yet to receive evaluable material?